https://doi.org/10.4081/reumatismo.2012.113

Psoriatic arthritis: treatment strategies using biologic agents

Vol. 64 No. 2 (2012)
Submitted: 30 April 2012
Accepted: 5 June 2012
Published: 5 June 2012
Psoriatic disease, psoriatic arthritis, therapy, biologic drugs, anti-TNFα agents
Abstract Views: 1108
PDF: 1133
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

S. D'Angelo
saldangelo@katamail.com
Lucania - San Carlo Hospital, Italy.
C. Palazzi
I. Olivieri
The traditional management of psoriatic arthritis (PsA) includes NSAIDs, corticosteroids and DMARDs. Advancement in the knowledge of the immunopathogenesis of PsA has been associated with the development of biologic agents which have revolutionized the management of the disease. Among biologics drugs, there are the 4 currently availablee anti-TNFα blocking agents (etanercept, infliximab, adalimumab and golimumab) which are more effective than traditional DMARDs on symptoms/signs of inflammation, quality of life, function, and in inhibiting the progression of the structural joint damage. Despite of the high cost, TNF inhibitors are costeffective on both the musculoskeletal and skin manifestations of psoriatic disease.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
S. D'Angelo, Lucania - San Carlo Hospital
Rheumatology Department

How to Cite

D’Angelo, S., Palazzi, C., & Olivieri, I. (2012). Psoriatic arthritis: treatment strategies using biologic agents. Reumatismo, 64(2), 113–121. https://doi.org/10.4081/reumatismo.2012.113

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Similar Articles

<< < 34 35 36 37 38 39 40 41 42 43 > >> 

You may also start an advanced similarity search for this article.